Anti Depression Drugs Market Rising Due to Mental Health Awareness and Novel Drug Launches | Takeda Pharmaceutical Co. Ltd, Pfizer Inc., Eli Lilly and Company, Viatris Inc.

The Global Anti Depression Drugs Market reached US$ 15.81 billion in 2023 and is expected to reach US$ 22.10 billion by 2031, growing at a CAGR of 4.3% during the forecast period 2024-2031.

Anti Depression Drugs Market Report by DataM Intelligence offers a detailed assessment of the global pharmaceutical and healthcare landscape, highlighting market size, key players, and critical growth drivers. With a focus on emerging drug technologies, evolving treatment paradigms, and regulatory frameworks, the report delivers strategic insights to support stakeholders in navigating the rapidly advancing sector from 2025 to 2033.

Download exclusive insights with our detailed sample report (Corporate Email ID gets priority access): https://www.datamintelligence.com/download-sample/anti-depression-drugs-market?ophp

Anti-depression drugs are medications used to manage depressive disorders by altering neurotransmitter activity in the brain. The market is witnessing consistent growth fueled by the global rise in mental health disorders, the launch of next-generation antidepressants, and increased public awareness and destigmatization of psychiatric treatment.

Anti Depression Drugs Market Competitors Overview:

Eli Lilly and Company, Viatris Inc., GlaxoSmithKline Plc., Zheijiang Huahai Pharmaceutical Co. Ltd., AstraZeneca Plc., Takeda Pharmaceutical Co. Ltd, Pfizer Inc., Aurobindo Pharma Limited, H. Lundbeck A/S and Teva Pharmaceutical Industries Ltd. among others

Important Industry Updates of 2023, 2024 and 2025:

✅ In June 2025, Raised $140 million to develop novel small-molecule treatments for severe depression (DT‐101 and others), targeting glutamate and GABA systems. This funding will support a global Phase 2 trial expected in 2026, with results due in 2027

✅ In April 2025, The UK-based biotech announced that its investors (notably Noetic Fund) are seeking up to $20 million at a ~$200 million valuation to support development of intranasal psychedelics for treatment-resistant depression. No formal deal yet confirmed.

✅ In January 2025, FDA approved esketamine nasal spray (Spravato) as the first standalone therapy for adults with treatment-resistant depression (who failed at least two oral antidepressants). This marks a landmark expansion of its use beyond adjunctive therapy

Methodology and Scope

The Anti Depression Drugs Market Report is built on a rigorous research methodology that integrates primary interviews, expert insights, and validated secondary data from company reports, industry publications, and reliable databases. Utilizing both bottom-up and top-down approaches, the analysis ensures high data accuracy through triangulation. The report covers current market dynamics, growth opportunities, and key strategic developments across global and regional markets.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/anti-depression-drugs-market?ophp

Anti Depression Drugs Market Segments Overview:

∎ By Drug Class (Selective Serotonin Reuptake Inhibitors (SSRIs), Monoamine Oxidase Inhibitors (MAOIs), Norepinephrine-dopamine Reuptake Inhibitor, Serotonin-norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Serotonin Modulators, Others)
∎ By Depression Disorder (Major Depressive Disorder, Bipolar depression, Obsessive-compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder , Others)

Regional Overview for Anti Depression Drugs Market:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking for in-depth insights? Grab the full report: https://www.datamintelligence.com/buy-now-page?report=anti-depression-drugs-market?ophp

The Report Covers:

➡ In-depth analysis of the demand-supply gap, market size estimates, SWOT and PESTEL analysis, along with global market forecasts.
➡ Strategic recommendations with a focused go-to-market approach.
➡ An unbiased evaluation of overall market performance.
➡ Region- and country-specific insights, with customized reports available upon request.
➡ Identification of high-potential and niche segments and regions demonstrating strong growth prospects.

People Also Ask:

➤ What are the current global trends in sales, production, imports, and exports within the «Keyword» market?
➤ Who are the leading manufacturers, and what are their production volumes, pricing strategies, and revenue metrics?
➤ What are the major opportunities and challenges facing vendors in this market?
➤ Which product categories, applications, or end-user segments are contributing most to market growth and share?
➤ What are the primary factors driving and restraining growth in the «Keyword» market?

Unlock 360° Market Intelligence with DataM Subscription Services:
https://www.datamintelligence.com/reports-subscription

✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drugs Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.